Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/28/23
Alector (ALEC) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 02/16/23
Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative DiseasesGlobeNewsWire • 11/29/22
MDA Breakout Stocks Week 40 - October 2022: Short-Term Picks To Give You An EdgeSeeking Alpha • 10/03/22
Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer's Disease (AD)GlobeNewsWire • 09/12/22
Wall Street Analysts Believe Alector (ALEC) Could Rally 58%: Here's is How to TradeZacks Investment Research • 08/09/22
Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare ConferenceGlobeNewsWire • 06/08/22
Alector (ALEC) to Report Q1 Results: Wall Street Expects Earnings GrowthZacks Investment Research • 04/27/22
Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical OfficerGlobeNewsWire • 03/29/22
Alector Presents AL001 (latozinemab) Data from the FTD-C9orf72 Cohort of the INFRONT-2 Phase 2 Clinical TrialGlobeNewsWire • 03/15/22